12 citations
,
April 1995 in “Journal of Medicinal Chemistry” In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.
25 citations
,
May 2003 in “Expert Opinion on Therapeutic Patents” This review examines patents and publications on steroid sulfatase inhibitors since 1999 and reports no new clinical results, highlighting their potential for treating estrogen- and androgen-driven conditions.
December 2011 in “Drug Research” The document shows the state of pharmaceutical patents as of 1999, focusing on treatments for various diseases.
37 citations
,
October 2006 in “Steroids” This paper describes recent advancements in the synthesis of thiasteroids but reports no new experimental results, noting that introducing heteroatoms in steroidal structures has potential biological effects.
106 citations
,
April 2010 in “ACS Nano” This study found that about 80% of known fullerene-binding proteins rank in the top 10% of scorers for C60 docking sites, confirming the accuracy of the predictive model used.